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Abstract
Islet transplantation is a minimally invasive treatment for severe diabetes. However, it often requires multiple donors to
accomplish insulin-independence and the long-term results are not yet satisfying. Therefore, novel ways to overcome these
problems have been explored. Isolated islets are fragile and susceptible to pro-apoptotic factors and poorly proliferative. In
contrast, mesenchymal stem cells (MSCs) are highly proliferative, anti-apoptotic and pluripotent to differentiate toward
various cell types, promote angiogenesis and modulate inflammation, thereby studied as an enhancer of islet function and
engraftment. Electrofusion is an efficient method of cell fusion and nuclear reprogramming occurs in hybrid cells between
different cell types. Therefore, we hypothesized that electrofusion between MSC and islet cells may yield robust islet cells for
diabetes therapy. We establish a method of electrofusion between dispersed islet cells and MSCs in rats. The fusion cells
maintained glucose-responsive insulin release for 20 days in vitro. Renal subcapsular transplantation of fusion cells prepared
from suboptimal islet mass (1,000 islets) that did not correct hyperglycemia even if co-transplanted with MSCs, caused slow
but consistent lowering of blood glucose with significant weight gain within the observation period in streptozotocin-
induced diabetic rats. In the fusion cells between rat islet cells and mouse MSCs, RT-PCR showed new expression of both rat
MSC-related genes and mouse b-cell-related genes, indicating bidirectional reprogramming of both b-cell and MSCs nuclei.
Moreover, decreased caspase3 expression and new expression of Ki-67 in the islet cell nuclei suggested alleviated apoptosis
and gain of proliferative capability, respectively. These results show that electrofusion between MSCs and islet cells yield
special cells with b-cell function and robustness of MSCs and seems feasible for novel therapeutic strategy for diabetes
mellitus.
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Introduction
Diabetes mellitus (DM) is a leading cause of morbidity and
mortality in industrialized countries, and the number of patients
affected is estimated to be 366 million in 2011 with an increase to
552 million by 2030 [1]. Among several types of DM, Type 1 DM
(T1DM) is characterized by the selective destruction of pancreatic
b-cells caused by an autoimmune attack or other unknown causes.
b-cell reconstruction is currently achieved only by either pancreas
or islet transplantation in clinical setting. Although clinical trials of
encapsulated islets that enable transplantation without immune
suppression are on-going [2], these transplantation therapies share
common problems of donor scarcity and adverse effects related to
immune suppression.
Islet transplantation is an effective therapy for T1DM, but
limited donor sources restrict it from becoming a major treatment
option [3,4]. In islet transplantation, a diabetic patient often
requires two or even three donor pancreata to accomplish insulin-
independence in current mainstream protocols, which makes the
problem of a donor shortage even more serious [5]. Even though
insulin-independence is achieved by islet transplantation, islet graft
function is rarely sustained with only 7.5% of these patients
remaining insulin-independent at 5 years post transplantation [3].
Loss of functional isolated islets occurs during the culture period
after isolation and purification [6]. It is established that apoptosis
triggered by withdrawal of growth factors [7], disruption of
extracellular matrix [6,8], and endotoxin contamination [9]
participates in islet loss under culture conditions. From these
reports, b-cells in isolated islets are susceptible to immune and
inflammatory factors and have minimal proliferation capacity, if
any.
Mesenchymal stem cells (MSCs), which were first identified by
Friedenstein and his colleagues [10], are known to be highly
proliferative and with anti-apoptotic potential [11]. MSCs derived
from bone marrow and other organs such as liver, umbilical cord
blood, placenta, and adipose tissue [12–15] have high proliferation
capacity and multipotency to differentiate toward various cell
types such as muscle, cartilage, and bone [16]. In addition, MSCs
have been shown to promote angiogenesis in vivo [17,18].
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Recent studies have shown that MSCs secrete several factors
that improve survival and function of transplanted islets. MSCs co-
cultured with islets secrete higher levels of anti-apoptotic signaling
molecules and improve glucose-stimulated insulin secretion
indexes [19]. Bone marrow cells are also shown to induce
endogenous b-cell proliferation and improvement of islet function
in vivo [20]. Furthermore, in co-transplantation of MSCs with
islets, MSCs improved the capacity of islet grafts to reverse
hyperglycemia compared with islets alone [21]. MSCs may also
enhance islet resistance to hypoxia/reoxygenation-induced apop-
tosis and dysfunction by promoting anti-apoptotic gene expression
[22]. Because of these favorable effects on islets, MSCs provide an
important approach for improvement of islet engraftment, thereby
decreasing the numbers of islets needed to achieve insulin-
independence [23].
Cell fusion occurs in physiological conditions such as normal
development and immune reaction [24–26]. Bone marrow-
derived stem cells fuse to several types of cells under normal
condition or after cell injury [27] and Tada M et al. have shown
that the nuclei of somatic cells can be reprogrammed by cell fusion
with embryonic stem cells [28]. Therefore, cellular transformation
may be induced by cell fusion between different types of cells
through nuclear reprogramming.
On the basis of above-mentioned knowledge, it was hypothe-
sized that cell fusion between MSC and b-cells may produce a
novel type of cells that combines b-cell function with MSC
characteristics including proliferation capacity and anti-apoptotic
ability.
In this study, we established a method of electrofusion between
MSCs and pancreatic islet cells and examined insulin secretion
capacity, mutual nuclear reprogramming, anti-apoptotic and
proliferative changes of islet cell nuclei in vitro and verified the
potential application of fusion cells to regenerative medicine for
diabetes mellitus in vivo.
Materials and Methods
Animals
Rats and mice were purchased from Shimizu Laboratory
Supplies Co. Ltd. (Kyoto, Japan). These animals were housed in
climate-controlled rooms with free access to pellet food and water.
The approval to conduct this experiment was obtained from the
Animal Care Committee of Institute for Frontier Medical
Sciences, Kyoto University, and the animals were treated
according to the experimental protocols under its regulations.
Reverse Transcription Polymerase Chain Reaction (RT-
PCR)
In the present study, total RNA was extracted using PureLink
RNA Mini kit (Invitrogen). RT-PCR was carried out using a
SuperScriptIII First-Strand cDNA synthesis (Invitrogen) and a
thermal cycler, iCycler (Bio-Rad). The primers used for PCR are
shown in the tables designated for each experiment. Unless
otherwise noted, PCR were performed for 35 cycles with each
cycle comprising 20 sec at 94uC, 30 sec at 65uC, and 1 min at
72uC. A final cycle comprised 5 min at 72uC. After PCR,
electrophoresis was performed by E-Gel iBase Power System and
E-Gel 4% Agarose (Invitrogen).
Table 1. Primer sequence for RT-PCR.
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Preparation of MSCs
The bone marrow was isolated from the tibias and femurs of
Lewis rats (male, 5 weeks old) or C57/BL6 mice (male, 4 weeks
old). After washing 3 times with Hank’s balanced salt solution and
centrifugation (1,000 rpm for 5 min at 4uC), cells were plated to
225 cm2 flask in the 1:1 mixture of Dulbecco’s modified Eagle’s
Medium and F12 (DMEM/F12; Gibco, NY, USA) with 12.5%
fetal bovine serum (FBS) and 1% antibiotics solution (mixture of
100 units/mL penicillin G sodium, 100 mg/mL streptomycin
sulfate and 25 mg/mL amphotericinB; Gibco) at 37uC in a
humidified atmosphere of 5% CO2 and 95% air. Non-adherent
cells were removed after 3-day culture. Adherent cells were
detached with 0.5% Trypsin-EDTA (Gibco) when the cells
become confluent after 4- to 5-day culture. MSCs of passages 5–
10 were used in the following experiments.
To characteraize MSCs, the cells were examined by RT-PCR
about four genes, i.e., CD34 and CD45 as negative markers and
CD73 and CD105 as positive markers. Bone marrow was served
as the control for MSCs. Primers are shown in Table 1.
Islet Isolation
Islets were isolated from male Lewis rats (11 weeks old, 280–
300 g) as described previously [29]. Briefly, rat pancreata were
digested by collagenase (typeXI, Sigma, St. Louis, USA) and then
the islets were separated by a dextran gradient. The islets were
further purified by handpicking and then were cultured in CMRL-
1066 medium (Gibco) with 10% FBS and antibiotics at 37uC in a
humidified atmosphere of 5% CO2 and 95% air. After 24-hour
culture, the islets were treated with 0.5% Trypsin-EDTA for
10 min at 37uC in order to prepare dispersed islet cells. Then,
dispersed cells were collected by centrifugation (1200 rpm, 5 min
at 4uC) and temporarily kept in the same medium at 37uC until
used for experiment within 20 min.
Cell Fusion
MSCs and dispersed islet cells were washed once in fusion
medium containing 5% glucose, 0.1 mM CaCH3(COO)2,
0.5 mM MgCH3(COO)2 and 0.3% bovine serum albumin
(BSA). The pH of the fusion medium was adjusted to 7.2–7.4
with L -histidine (all chemicals were from Sigma). After
centrifugation, the cells were re-suspended in the fusion medium
without BSA. MSCs (16106) and dispersed islet cells (16106) were
suspended in 100 ml of fusion medium and placed in a specially
designed fusion chamber made of two concentric oval electrodes
(6c m616 cm, Cat. No. CUY480G2, NEPA GENE Co., Ltd.
Chiba, JAPAN). For electrofusion, a pulse generator (ECM 2001,
BTX Instrument, Genetronics, CA, USA) was used. Electrofusion
involved two independent but consecutive steps. The first
treatment is to bring cells in close contact by dielectrophoresis,
which can be accomplished by exposing cells to an alternating
electric field (AC) of relatively low voltage. Then, cell fusion was
triggered by applying a single squarewave pulse (DC) to induce
reversible cell membrane break-down in the zone of membrane
contact. For this study, electrofusion was perfomed by AC of 35 V
for 20 sec followed by DC of 350 V for 25 msec based on our past
study [30].
Validation of Cell Fusion
To determine fusion efficiency, cell mixtures before cell fusion
and fusion cells were stained by Giemsa staining after 24 hour
culture. In order to confirm cell fusion between MSCs and islet-
cells, MSCs and dispersed islet cells were pre-labeled with the
SYTO11 (Invitrogen, CA, USA) and Vybrant Dil (Santa Cruz,
CA, USA), respectively, following manufacturer’s instructions.
Cells before and after cell fusion were examined under a
fluorescence microscope (Olympus IX70, Tokyo, Japan) after an
overnight culture.
Insulin Secretion Test
In vitro glucose challenge test was performed in the prepared
cells as follows after 1-, 10- and 20-day culture: (1) MSCs only
(26104 cells per well), (2) Islets only (20 Islets), (3) Non-fused MSCs
(26104 cells) with islets (20 islets), (4) Non-fused MSCs (26104
cells) with dispersed islet cells prepared from 20 islets, (5) Fusion
cells of MSCs (26104 cells) and dispersed islet cells prepared from
20 islets. For glucose challenge test, all groups were pre-incubated
in RPMI-1640 with 0.1% BSA containing 3.3 mM glucose at
37uC for 1 hour. After pre-incubation, the medium was replaced
with the same medium for 1 hour. Then, the medium was
replaced with RPMI-1640 with 0.1% BSA containing 16.7 mM
glucose for 1 hour. Finally, the medium was replaced with RPMI-
1640 with 0.1% BSA containing 3.3 mM glucose for 1 hour.
Insulin concentration of the media was measured using a rat
insulin ELISA kit (Shibayagi, Gunma, Japan).
Table 3. Primer sequence for RT-PCR.
Animal Gene
Rat caspase3 Forward CTTTGCGCCATGCTGAAACT
Reverse ATGACGACCTGGAACATCGG
doi:10.1371/journal.pone.0064499.t003
Table 4. Primer sequence for RT-PCR.
Animal Gene
Rat Ki-67 Forward CTTTGCGCCATGCTGAAACT
Reverse ATGACGACCTGGAACATCGG
doi:10.1371/journal.pone.0064499.t004
Figure 1. Gene expression of CD34, CD45, CD73 and CD105 in
rat MSCs, rat bone marrow, mouse MSCs and mouse bone
marrow.
doi:10.1371/journal.pone.0064499.g001
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Nuclear Reprogramming
In order to investigate whether nuclear reprogramming occurs
in MSCs and/or islet cells, mouse MSCs and rat islet cells were
fused and expressions of typical MSC genes (Oct3/4, CD106, and
Sca1) and islet genes (Insulin-1, Pdx-1 and Ngn3) were examined
by RT-PCR after 1-day culture using the primers designed for
both rat and mouse genes.
Total RNA was extracted from MSCs of mouse and rat, rat
islets, MIN-6 cells [31] and the fusion cells. Co-culture of mouse
MSCs with rat islets (MM+RI) was served as the control for fusion
cells. The primers are shown in Table 2.
Islet Cell Apoptosis
In order to investigate whether electrofusion of rat MSCs induce
changes on rat islet cell apoptosis, rat caspase3 gene expression
was examined by RT-PCR in five groups described in insulin
secretion test after 1-day culture. The primers used for PCR are
shown in Table 3. PCR were performed for 28, 30, 32, 34 and 36
cycles with each cycle comprising 10 sec at 98uC, 30 sec at 65uC,
and 1 min at 72uC. A final cycle comprised 5 min at 72uC. After
PCR, electrophoresis was performed by E-Gel iBase Power System
and E-Gel 4% Agarose (Invitrogen). Moreover, in order to detect
apoptotic cells, all groups were stained with annexin V and
propidium iodide (PI) using Annexin V-FITC (Beckman Coulter,
Tokyo, Japan, IM2375) following manufacturer’s instructions.
Briefly, cell samples were suspend in accompanying buffer on ice.
FITC-labeled annexin V solution and PI solution were added and
the samples were kept on ice for 10 minutes in the dark. Then, the
samples were observed under a fluorescence microscope (KEY-
ENCE BZ-8000, Tokyo, Japan).
Islet Cell Proliferation
In order to investigate whether islet cell proliferation occurs in
fusion cells, fusion cells were made from mouse MSCs and rat islet
cells. Expressions of rat Ki-67 gene was examined by RT-PCR
using the primers shown in Table 4 after 1- and 5-day culture.
Mouse MCSs, rat MSCs, rat islets and co-culture of mouse MSCs
with rat islets were served as controls.
Transplantation Experiment
In order to investigate whether fusion cells can really control
hyperglycemia, the effect of fusion cell transplantation was
observed in comparison to optimal (2,000 islet per rat) and
suboptimal (1,000 islet per rat) islet mass transplantation. Lewis
rats (male, 11 weeks old, 280–300 g) were made diabetic with
streptozotocin (55 mg/kg body weight, i.p.) for recipients. One
week after the injection, blood glucose (BG) was measured by tail
vein sampling using Fuji Dry Chem system (Dri-chem 3000
colorimetric analyzer, Fujifilm, Tokyo, Japan) and rats with non-
fasting BG higher than 500 mg/dL were used for recipients. Rats
were divided into seven groups as follows: Group1; Normal
control group (n = 6), Group 2; sham operated DM group (n = 6),
Group 3; sub-optimal islet group (1000 islets: n = 9), Group 4;
optimal islet group (2000 islets: n = 5), Group 5; MSCs group
(16106 cells: n = 9), Group 6; Non-fused cell group (dispersed islet
cells from 1000 islets and MSCs 16106 cells: n = 9), Group 7;
Fusion cell group (fusion cells processed from dispersed cells of
1000 islets and MSCs 16106 cells: n = 9). Cells were transplanted
into the left renal subcapsular space through the skin incision on
the lumbar dorsum under general anesthesia of isoflurane
inhalation. After transplantation, BG and body weight were
measured on postoperative days (POD) 3, 7, 14, 21, 28, 35, 42, 49,
56, 63, 70, 77, 84, and 91.
Statistical Analysis
Results are presented as mean 6 SE as indicated in the figure
legends. Two-way ANOVA for repeated-measures in SPSS 14.0




MSCs have been established using various methods by many
researchers. In the present study, our rat and mouse bone marrow-
derived cells showed morphology similar to typical MSCs and
Figure 2. Results of reverse transcription PCR for reprogram-
ming after 1-day culture. PCR was carried out by primers designed
for rat genes (a) and mouse genes (b). F: Fusion cells between mouse
MSCs and rat islet cells, MM: mouse MSCs, M6: MIN-6, RM: rat MSCs, RI:
rat islets and MM+RI: co-culture of mouse MSCs with rat islets (non-
fused).
doi:10.1371/journal.pone.0064499.g002
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expressed several MSC-specific markers such as CD73 and
CD105 (Fig. 1) in addition to sca-1 and CD106 (Fig. 2-a, b). On
the other hand, CD34 and CD45 that were expressed in original
bone marrow cells were not detected (Fig. 1). These results indicate
that our bone marrow-derived cells were consistent with putative
MSCs.
Validation of Cell Fusion
Rat MSCs and dispersed rat islet-cells were successfully fused by
our method. By Giemsa staining, multinuclear cells were observed
after cell fusion whereas such cells were not observed without cell
fusion (Fig. 3). By electrofusion of SYTO11-labeled MSCs and
Vybrant Dil-labeled islet cells, cells double positive for SYTO11
and Vybrant Dil were observed after cell fusion, whereas such cells
were not observed without cell fusion (Fig. 4).
Insulin Secretion Test
In comparison among the cultured cells of MSCs alone, islets
alone, MSCs and islets without cell fusion, MSCs and dispersed
islet cells without cell fusion and fusion cells of MSCs and
dispersed islet cells, all groups except for MSCs alone showed
glucose-responsive insulin release after 1-day culture (Fig. 5-a).
After 10-day culture, islets alone lost the glucose responsiveness
but dispersed islet cells with MSCs and fusion cells maintained it
(Fig. 5-b). Although undispersed islets with MSCs seemed to
maintain responsiveness a, the insulin concentration was lower and
the response was not statistically significant (Fig. 5-b). After 20-day
culture, all groups except fusion cells showed loss of glucose-
responsiveness (Fig. 5-c). In dispersed islet cells with MSCs,
although significant increase was observed between the first
3.3 mM and 16.7 mM, decreased between 16.7 mM and the last
3.3 mM was not observed. Therefore, these cells were considered
to have lost good glucose-responsiveness.
Figure 5-d shows microscopic morphology of the tested cells.
Figure 5-d (A–E) shows the cells after 1-day culture, figure 5-d (F–
J) shows those after 10-day culture and figure 5-d (K–O) shows
cells after 20-day culture. In islets alone, most of the islets were
destroyed after 20-day culture (Fig. 5-d: L). In the co-cultures of
Figure 3. Giemsa staining in electrofusion cells (a) and non-fused cells (b). Scale bar: 20 mm.
doi:10.1371/journal.pone.0064499.g003
Figure 4. Fluorescence staining in electrofusion cells (a) and non-fused cells (b). Left upper panel shows light microscopic view. Islet-cells
were stained by Vybrant-Dil (red: right upper panel), and MSCs were stained by SYTO11 (green: left lower panel). Right lower panel shows merge
(arrow head: fusion cell). Fusion cells show yellowish nuclei since green nuclei are involved in red cytoplasm.
doi:10.1371/journal.pone.0064499.g004
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MSCs and islets, a few islets maintained their morphology and
they were attached to colonies of MSCs (Fig. 5-d: M). In co-culture
of MSCs and dispersed islet-cells, re-clustering of islet cells was
observed although it is not known if such clusters contained MSCs
(Fig. 5-d: N). In fusion cells, most cells were attached to the bottom
of the culture dish and cell number appeared to increase with time
(Fig. 5-d: E, J, O).
Nuclear Reprogramming
MSC- and b-cell-related gene expression of fusion cells between
mouse MSCs and rat islets was examined. Primers designed for rat
genes (Table 2) did not react with the cDNA derived from mouse
MSCs and MIN-6, a mouse b-cell line. Rat islet markers such as
Insulin-1, Pdx-1 (Pancreatic duodenal homeobox 1), and Ngn3
(Neurogenin 3) were not expressed in rat MSCs and conversely,
rat MSC markers such as Sca-1, CD106 and Oct3/4 were not
expressed in rat islets. Fusion cells prepared from rat islets and
mouse MSCs showed new expression of the rat MSC markers
(Fig. 2-a). Similarly, primers designed for mouse genes (Table 2)
did not react with the cDNA derived from rat islets and MSCs.
Mouse islet markers were not expressed in mouse MSCs. Mouse
MSC markers except for Oct3/4, were not expressed in MIN-6.
Fusion cells showed new expression of the mouse islet markers
(Fig. 2-b). On the other hand, such changes in gene expression
were not observed in co-culture of mouse MSCs and rat islets
(Fig. 2-a, b). These results indicate that nuclei of both MSCs and
islet cells were mutually reprogrammed by one another in fusion
cells.
Islet Cell Apoptosis
Gene expression of caspase3 was detected in all groups except
MSCs. PCR product was readily detected after 28 cycles in islet
group and MSCs and dispersed islet cells group. On the other
hand, in MSCs and islet group and fusion group, it was detected
after 30 cycles. All groups reached plateau by 36 cycles (Fig. 6-a).
Therefore, caspase3 expression was reduced in fusion cells in
comparison to that in co-culture of MSCs and dispersed islet cells.
Annexin and PI positive cells were scarcely detected in MSCs.
However, in other groups (Islet, MSCs and islet, MSCs and
dispersed islet cell, fusion cell), they were observed after 1-day
culture. Co-culture of MSCs with islets appeared to reduce
annexin and PI positive cells in comparison to islet alone. Annexin
and PI positive cells appeared to be reduced in fusion cells in
comparison to co-culture of MSCs and dispersed islet cells (Fig. 6-
b).
Islet Cell Proliferation
On day 1, only rat MSCs expressed rat Ki-67. However, on day
5, fusion cells newly expressed rat Ki-67. Ki-67 expression was not
detected in co-culture of mouse MSCs and rat islet (Fig. 7). This
result suggests that rat islet nuclei obtained proliferative capability
after cell fusion with mouse MSCs.
In vivo Transplantation
Effect of renal subcapsular transplantation of fusion cells was
examined in seven groups as follows: Group1; Normal control
(n = 6), Group 2; sham operated streptozotocin-induced DM rats
(n = 6), Group 3; sub-optimal islet mass (1000 rat islets: n = 9),
Group 4; optimal islet mass (2000 islets: n = 5), Group 5; MSCs
alone (16106 cells: n = 9), Group 6; Non-fused cell mix of
dispersed islet cells from 1000 islets and MSCs 16106 cells (n = 9),
Group 7; Fusion cell processed from dispersed cells from 1000
islets and MSCs 16106 cells (n = 9). Figures 8-a and b show
changes in blood glucose (BG) and body weight, respectively. In
Figure 5. In vitro insulin secretion and microscopic morphology of the tested cells. a–c: insulin secretion after 1, 10, and 20 day cultures,
respectively. (mean6SEM: n= 3, *:p,0.05). d: microscopic morphology, scale bar: 20 mm A–E: after 1 day culture. F–J: after 10 days of culture. K–O:
after 20 days of culture.
doi:10.1371/journal.pone.0064499.g005
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group 4 (2000 islets), BG was decreased promptly and hypergly-
cemia was corrected to the normal range ever since POD 40. In
the same group, body weight also showed a significant increase
with a slope similar to the control group. There were no significant
parametric changes either in BG or body weight in group 3 (1000
islets). Transplantation of MSCs alone in group 5 did not show any
effect on BG or body weight in comparison to DM control of
group 2. In group 6 (non-fused cell), BG did not decrease less than
400 mg/mL and body weight was slightly increased. Group 7
(fusion cell) showed continuous decrease in BG during the
observation period and a greater increase in body weight
compared to group 6 was observed. A significant difference was
detected between group 7 and group 6 both in BG and body
weight as well as between group 7 and group 3 (p,0.05, Fig. 8-a,
b).
Figure 6. a: Caspase3 gene expression for each group by 28, 30, 32, 34 and 36 PCR cycles. b: Annexin staining for each group. Upper
panels show light microscopic view. Middle panels show annexin staining (green: cell membrane), and lower panels show propidium iodide staining
(red: nuclear). Scale bar: 20 mm.
doi:10.1371/journal.pone.0064499.g006
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Discussion
In this study, fusion cells between islet cells and MSCs were
successfully prepared by electrofusion as shown in Figures 3 and 4.
The fusion cells maintain sustained b-cell function in vitro and
ameliorate hyperglycemia in a progressively increasing manner,
suggesting potential clinical use of these fusion cells for diabetes
therapy. In the literature, Barrera-Escorcia E, et al. have reported
electrofusion of donor islet cells with poorly characterized dermal
cells of allogeneic recipient in rats. They transplanted the fusion
cells to examine the modulation of immunogenicity without in vitro
characterization [32]. Although a slight improvement was seen in
several parameters including blood glucose levels, they failed to
obtain the reversion of the diabetic profile with transplantation of
their fusion cells.
Artificial cell fusion was first enabled through the discovery of
Sendai virus by Okada Y, et al. [33]. Then, polyethylene glycol
method [34] and electrofusion [35] were put to practical use.
Among these methods, electrofusion appears to be the most
efficient in order to prepare large number of cells necessary for
transplantation therapy. In addition, electrofusion is suitable for
clinical used because it does not need special chemicals or
biological materials that may affect the safety of the processed
cells.
In the literature, Soleimani M et al. [36] reported a protocol for
isolation and culture of MSCs from mouse bone marrow using
primary culture with frequent medium changes, suggesting that
MSCs can be obtained without positive or negative selection.
Many other researchers use the similar protocols without cellular
selection to obtain MSCs. In the present study, bone marrow-
derived cells show morphology similar to typical MSCs and
expressed several MSC-specific markers, i.e., CD73 (also known as
ecto-59-nucleotidase, differentiation marker of lymphocytes),
CD105 (also known as Endoglin, a component of TGF-beta
receptor), sca-1 (also known as Ly-6A, expressed in hematopoietic
stem cells, skeletal muscle cells, epithelial stem cells, lymphocytes
and macrophages) and CD106 (also known as VCAM-1,
expression is strongly downregulated in MSCs after differentiation
to adipo-, osteo-, and chondrocytes) [37–38]. Expression of these
markers is known to be involved in the minimal criteria for
defining multipotent MSCs [39]. On the other hand, as to the
negative markers, CD34 and CD45, that are well known as
hematopoietic stem cells markers, were positive in original bone
marrow cells but were not detected in MSCs. Lack expression of
these markers is also involved in the minimal criteria [39]. From
these results, we consider that our bone marrow-derived cells used
in the present study were consistent with putative MSCs.
In the present in vitro study, co-culture of islet cells with MSCs
enhanced sustainability of b-cell function to certain extent and cell
fusion of islet cells and MSCs could further enhanced it. The
protective effect of MSCs on islets was previously reported [22]
and our co-culture study confirmed this. Additionally, the present
study further showed that cell fusion of islet cells with MSCs
dramatically enhances sustainability of b-cell function in vitro.
Present RT-PCR examination for reprogramming clearly
showed that nuclei of both islet cells and MSCs were mutually
reprogrammed by electrofusion. Therefore, these fusion cells can
be considered as special cells with b-cell function and robustness of
MSCs. In fact, we observed sustained insulin secretion during the
experimental period in vitro and this seems to be caused by the
MSCs’ antiapoptotic nature. On the other hand, although the
protective effect of MSCs on co-cultured islets is often attributed to
signaling molecules and cytokines released from MSCs [22], co-
Figure 7. Rat Ki-67 gene expression of each group by RT-PCR.
MM: mouse MSCs, RM: rat MSCs, RI: rat islets, Mix: co-culture of mouse
MSCs with rat islets (non-fused) and F: Fusion cells between mouse
MSCs and rat islet cells.
doi:10.1371/journal.pone.0064499.g007
Figure 8. Results of blood glucose (a) and body weight (b) in in vivo transplantation study. Group 1(Normal control, n = 6,&), Group
2(DM-sham, n = 6,N), Group 3(Islet-1000, n = 9,¤), Group 4(Islet-2000, n = 5,#), Group 5(MSCs, n = 9,%), Group 6(Mix, n = 9,6), Group 7(Fusion,
n = 9,m). *: p,0.05 vs Group 6.
doi:10.1371/journal.pone.0064499.g008
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culture of MSCs with islet cells did not cause reprogramming of
islet cell nuclei (Fugure 5-a, b).
Palermo A. et al. [40] have reported nuclear reprogramming in
fusion cells of human keratinocytes and mouse muscle cells and
found that extensive changes were observed within 4 days. They
also reported that, depending on the ratio of the cell number of
two cell types, either phenotype could be dominant. In the present
reprogramming study, we examined only one ratio of 1,000 islets
and 16106 MSCs, that can be estimated approximately 1:1 cell
ratio at only one time point, after an over night culture.
Apparently, the influence of cell ratio and time point awaits
further investigation.
As to the anti-apoptotic nature of MSCs, caspase3 gene
expression was decreased in co-culture of MSCs with islets in
comparison to islet alone (Fig. 6-a), suggesting anti-apoptotic effect
of MSCs on islets. MSCs, however, did not show the effect when
co-cultured with dispersed islet cells in which apoptotic tendency is
thought to be increased (Fig. 6-a). Finally, caspase3 gene
expression was decreased in fusion cells between MSCs and
dispersed islet cells (Fig. 6-a). These results indicate that
electrofusion of MSCs can inhibit apoptotsis of islet cell nuclei
even after they are dispersed.
In the present in vivo transplantation study, sub-optimal number
of islet cells fused with MSCs gradually normalized the blood
glucose levels in weeks. This suggests that the b-cell function of
transplanted fusion cells was gradually enhanced. Some other
studies have reported that co-transplantation of islets with MSCs
could facilitate engraftment of the islets [21]. However, in the
present study, we have failed to show this in the group 6 of non-
fused islet cells and MSCs co-transplantation, probably because
islet mass of 1,000 islets was too small to show the effect even
transplanted with MSCs. On the other hand, fusion cells between
islet cells and MSCs showed significant effect of transplantation in
comparison to the group 3 (sub-optimal islet number) and even to
the group 6 (co-tra*nsplantation with MSCs). These results
indicate that cell fusion with MSCs provides a more potent
facilitative effect on islet transplantation than co-transplantation of
MSCs.
The mechanism of this observation remains to be elucidated.
But, from present in vitro study, one possibility is sustainability of b-
cell function that overcomes glucose toxicity caused by hypergly-
cemia. Another possibility is proliferation of the fusion cells that
exert b-cell function. Although it is not quantitatively analyzed in
the present study, cell number of fusion cells appeared to increase
during culture period as shown in Fig. 5-d: E, J and O.
Furthermore, new expression of rat Ki-67 in fusion cells suggests
that islet cell nuclei obtain proliferation capability at least 5 days
after cell fusion (Fig. 7). Therefore, fusion cells between islet cells
and MSCs seem durable and proliferative to exert increasing b-
cell function after transplantation.
Possible relationship between carcinogenesis and interaction or
cell fusion of bone marrow-derived cells is suggested [41].
Although we did not find any tumor formation at the transplan-
tation site of fusion cells at POD 91, tumorigenicity of fusion cells
should be carefully addressed in the future studies.
In conclusion, this study showed that electrofusion of islet cells
with MSCs is an efficient method to obtain potent and robust
insulin-secreting cells that can potentially have a clinical interest
since it could help to reduce the number of islet cells needed to
achieved a therapeutic benefit in diabetic patients.
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